EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology firm working to develop the world’s most potent vaccines, at this time introduced the pricing of an roughly $32.5 million underwritten public providing of its frequent inventory (or pre-funded warrants to buy frequent inventory in lieu thereof) and accompanying frequent warrants to buy frequent inventory (or pre-funded warrants to buy frequent inventory in lieu thereof), earlier than deducting underwriting reductions and commissions and providing bills.
The providing consists of (i) 8,333,333 shares of frequent inventory and accompanying frequent warrants to buy as much as 8,333,333 shares of frequent inventory at a per share train value of $1.65 (supplied, nevertheless, that the purchaser could elect to train the frequent warrants for pre-funded warrants in lieu of shares of frequent inventory at an train value of $1.65 minus $0.0001, the train value of every pre-funded warrant), at a mixed public providing value of $1.50 per share and accompanying frequent warrant and (ii) to a sure investor in lieu of frequent inventory, pre-funded warrants to buy as much as 13,334,222 shares of frequent inventory at a per share train value of $0.0001 and accompanying frequent warrants to buy as much as 13,334,222 shares of frequent inventory at a per share train value of $1.65 (supplied, nevertheless, that the purchaser could elect to train the frequent warrants for pre-funded warrants in lieu of shares of frequent inventory at an train value of $1.65 minus $0.0001, the train value of every pre-funded warrant) at a mixed public providing value of $1.4999 per pre-funded warrant and accompanying frequent warrant, which represents the per share mixed buy value for the frequent inventory and accompanying frequent warrants much less the $0.0001 per share train value for every such pre-funded warrant. The accompanying frequent warrants might be instantly exercisable for shares of frequent inventory or pre-funded warrants in lieu thereof, and can expire on the twelve-month anniversary of the date of issuance. The entire shares of frequent inventory, accompanying frequent warrants and pre-funded warrants are being supplied by Gritstone bio. The providing is predicted to shut on or about April 4, 2024, topic to the satisfaction of customary closing circumstances.
TD Cowen and Evercore ISI are appearing because the joint book-running managers for the providing.
The securities are being supplied by Gritstone bio pursuant to a registration assertion on Kind S-3 (File No. 333-263455) beforehand filed and declared efficient by the Securities and Change Fee (“SEC”). A remaining prospectus complement and accompanying base prospectus referring to and describing the phrases of the proposed providing might be filed with the SEC and might be obtainable on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and accompanying base prospectus can also be obtained, when obtainable, from: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by phone at (855) 495-9846 or by electronic mail at TD.ECM_Prospectus@tdsecurities.com; or Evercore Group L.L.C., Consideration: Fairness Capital Markets, 55 East 52nd Road, thirty fifth Flooring, New York, New York 10055, by phone at (888) 474-0200, or by electronic mail at ecm.prospectus@evercore.com.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities in any state or jurisdiction through which such supply, solicitation, or sale could be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology firm that goals to develop the world’s most potent vaccines. We leverage our modern vectors and payloads to coach a number of arms of the immune system to assault crucial illness targets. Independently and with our collaborators, we’re advancing a portfolio of product candidates to deal with and forestall viral illnesses and strong tumors in pursuit of enhancing affected person outcomes and eliminating illness.
Cautionary Be aware Concerning Ahead-Trying Statements
This press launch incorporates forward-looking statements inside the which means of the “secure harbor” provisions of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements replicate the present beliefs and expectations of administration and embrace, however are usually not restricted to, statements relating to the timing for closing of the providing, the satisfaction of customary closing circumstances associated to the providing and sale of securities and the Firm’s capacity to finish the providing. As well as, when or if used on this press launch, the phrases “could,” “might,” “ought to,” “anticipate,” “imagine,” “estimate,” “anticipate,” “intend,” “plan,” “predict” and comparable expressions and their variants, as they relate to the Firm could establish forward-looking statements. Ahead-looking statements are neither historic details nor assurances of future efficiency. Though the Firm believes the expectations mirrored in such forward-looking statements are cheap, the Firm can provide no assurance that such expectations will show to be appropriate. Readers are cautioned that precise outcomes, ranges of exercise, security, efficiency or occasions and circumstances might differ materially from these expressed or implied within the Firm’s forward-looking statements attributable to a wide range of components, together with dangers and uncertainties associated to market circumstances and the satisfaction of closing circumstances associated to the underwritten public providing, the uncertainties inherent within the drug growth course of, together with the Firm’s applications’ medical stage of growth, the method of designing and conducting preclinical and medical trials, the regulatory approval processes, the timing of regulatory filings, the challenges related to manufacturing drug merchandise, the Firm’s capacity to efficiently set up, shield and defend its mental property and different issues that would have an effect on the sufficiency of current money to fund operations, and different dangers and uncertainties described beneath the heading “Threat Elements” in paperwork the Firm information on occasion with the SEC, together with the Firm’s annual report on Kind 10-Ok filed on March 5, 2024, and its different SEC filings. Accordingly, readers are cautioned to not place undue reliance on these forward-looking statements. Besides as required by relevant regulation, we don’t plan to publicly replace or revise any forward-looking statements contained herein.
Gritstone bio Contacts
Buyers:
George E. MacDougall
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
